Abstract
Purpose of Review
Men and women differ in the prevalence, pathophysiology and control rate of hypertension in an age-dependent manner. The renal endothelin system plays a central role in sex differences in blood pressure regulation by control of sodium excretion and vascular function. Improving our understanding of the sex differences in the endothelin system, especially in regard to blood pressure regulation and sodium homeostasis, will fill a significant gap in our knowledge and may identify sex-specific therapeutic targets for management of hypertension.
Recent Findings
The current review will highlight evidence for the potential role for endothelin system in the pathophysiology of hypertension within three female populations: (i) postmenopausal women, (ii) women suffering from preeclampsia, or (iii) pulmonary arterial hypertension.
Summary
Clinical trials that specifically address cardiovascular and renal diseases in females under different hormonal status are limited. Studies of the modulatory role of gonadal hormones and sex-specific mechanisms on critically important systems involved, such as endothelin, are needed to establish new clinical practice guidelines based on systematic evidence.
Similar content being viewed by others
References
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292.
Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801–11.
Granger JP, Abram S, Stec D, Chandler D, Speed J, LaMarca B. Endothelin, the kidney, and hypertension. Curr Hypertens Rep. 2006;8(4):298–303.
Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. Endothelin. Pharmacol Rev. 2016;68(2):357–418.
Levin ER. Endothelins. N Engl J Med. 1995;333(6):356–63.
Hall JE, Granger JP, do Carmo JM, da Silva AA, Dubinion J, George E, et al. Hypertension: physiology and pathophysiology. Compr Physiol. 2012;2(4):2393–442.
Elijovich F, Weinberger MH, Anderson CA, Appel LJ, Bursztyn M, Cook NR, et al. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension. 2016;68(3):e7–e46.
Pollock DM, Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol. 2001;281(1):F144–50.
Speed JS, D'Angelo G, Wach PA, Sullivan JC, Pollock JS, Pollock DM. High salt diet increases the pressor response to stress in female, but not male ETB-receptor-deficient rats. Physiol Rep. 2015;3(3):e12326.
Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9699):1423–31.
Gohar EY, Giachini FR, Pollock DM, Tostes RC. Role of the endothelin system in sexual dimorphism in cardiovascular and renal diseases. Life Sci. 2016;159:20–9.
Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci. 2012;91(13–14):528–39.
Schulman IH, Aranda P, Raij L, Veronesi M, Aranda FJ, Martin R. Surgical menopause increases salt sensitivity of blood pressure. Hypertension. 2006;47(6):1168–74.
Wassertheil-Smoller S, Anderson G, Psaty BM, Black HR, Manson J, Wong N, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative. Hypertension. 2000;36(5):780–9.
Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and nutrition examination survey, 1988–1991. Hypertension. 1995;25(3):305–13.
Khalil RA. Sex hormones as potential modulators of vascular function in hypertension. Hypertension. 2005;46(2):249–54.
Reckelhoff JF. Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. Hypertension. 2005;45(2):170–4.
Tremollieres FA, et al. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis. 1999;142(2):415–23.
Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290(2):199–206.
Kim JK, Alley D, Seeman T, Karlamangla A, Crimmins E. Recent changes in cardiovascular risk factors among women and men. J Women's Health (Larchmt). 2006;15(6):734–46.
Wilcox JG, Hatch IE, Gentzschein E, Stanczyk FZ, Lobo RA. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril. 1997;67(2):273–7.
Komatsumoto S, Nara M. Changes in the level of endothelin-1 with aging. Nihon Ronen Igakkai Zasshi. 1995;32(10):664–9.
Saltevo J, Puolakka J, Ylikorkala O. Plasma endothelin in postmenopausal women with type 2 diabetes mellitus and metabolic syndrome: a comparison of oral combined and transdermal oestrogen-only replacement therapy. Diabetes Obes Metab. 2000;2(5):293–8.
Son WM, Sung KD, Cho JM, Park SY. Combined exercise reduces arterial stiffness, blood pressure, and blood markers for cardiovascular risk in postmenopausal women with hypertension. Menopause. 2017;24(3):262–8.
Webb CM, Ghatei MA, McNeill JG, DCRR, Collins P. 17beta-estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation. 2000;102(14):1617–22.
Wenner MM, Sebzda KN, Kuczmarski AV, Pohlig RT, Edwards DG. ETB receptor contribution to vascular dysfunction in postmenopausal women. Am J Physiol Regul Integr Comp Physiol. 2017;313(1):R51–7.
Gohar EY, Yusuf C, Pollock DM. Ovarian hormones modulate endothelin A and B receptor expression. Life Sci. 2016;159:148–52.
Kitamura K, Tanaka T, Kato J, Eto T, Tanaka K. Regional distribution of immunoreactive endothelin in porcine tissue: abundance in inner medulla of kidney. Biochem Biophys Res Commun. 1989;161(1):348–52.
Gohar EY, Kasztan M, Becker BK, Speed JS, Pollock DM. Ovariectomy uncovers purinergic receptor activation of endothelin-dependent natriuresis. Am J Physiol Renal Physiol. 2017;313(2):F361–9.
Li P, Liu H, Sun P, Wang X, Wang C, Wang L, et al. Chronic vagus nerve stimulation attenuates vascular endothelial impairments and reduces the inflammatory profile via inhibition of the NF-kappaB signaling pathway in ovariectomized rats. Exp Gerontol. 2016;74:43–55.
Lima R, Yanes LL, Davis DD, Reckelhoff JF. Roles played by 20-HETE, angiotensin II and endothelin in mediating the hypertension in aging female spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2013;304(3):R248–51.
Sava RI, March KL, Pepine CJ. Hypertension in pregnancy: taking cues from pathophysiology for clinical practice. Clin Cardiol. 2018;41(2):220–7.
Palei AC, Spradley FT, Warrington JP, George EM, Granger JP. Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol (Oxf). 2013;208(3):224–33.
Lu YP, Hasan AA, Zeng S, Hocher B. Plasma ET-1 concentrations are elevated in pregnant women with hypertension-meta-analysis of clinical studies. Kidney Blood Press Res. 2017;42(4):654–63.
Mastrogiannis DS, O’Brien WF, Krammer J, Benoit R. Potential role of endothelin-1 in normal and hypertensive pregnancies. Am J Obstet Gynecol. 1991;165(6 Pt 1):1711–6.
LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension. 2009;54(4):905–9.
LaMarca B, Amaral LM, Harmon AC, Cornelius DC, Faulkner JL, Cunningham MW. Placental ischemia and resultant phenotype in animal models of preeclampsia. Curr Hypertens Rep. 2016;18(5):38.
Bakrania BA, Spradley FT, Satchell SC, Stec DE, Rimoldi JM, Gadepalli RSV, et al. Heme oxygenase-1 is a potent inhibitor of placental ischemia-mediated endothelin-1 production in cultured human glomerular endothelial cells. Am J Physiol Regul Integr Comp Physiol. 2018;314(3):R427–32.
Saleh L, Verdonk K, Visser W, van den Meiracker AH, Danser AHJ. The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia. Ther Adv Cardiovasc Dis. 2016;10(5):282–93.
Jain A. Endothelin-1: a key pathological factor in pre-eclampsia? Reprod BioMed Online. 2012;25(5):443–9.
Murphy SR, LaMarca BBD, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension. 2010;55(2):394–8.
George EM, Granger JP. Endothelin: key mediator of hypertension in preeclampsia. Am J Hypertens. 2011;24(9):964–9.
Saleh L, Danser JA, van den Meiracker AH. Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment. Curr Opin Nephrol Hypertens. 2016;25(2):94–9.
Bakrania B, Duncan J, Warrington J, Granger J. The endothelin type A receptor as a potential therapeutic target in preeclampsia. Int J Mol Sci. 2017;18(3):522.
Thaete LG, Khan S, Synowiec S, Dayton BD, Bauch J, Neerhof MG. Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy. Life Sci. 2012;91(13–14):583–6.
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–58.
Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996;226(2):324–8.
Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001;26(1):25–35.
Karumanchi SA. Angiogenic factors in preeclampsia: implications for clinical practice. BJOG. 2018 (in press).
Karumanchi SA. Angiogenic factors in preeclampsia: from diagnosis to therapy. Hypertension. 2016;67(6):1072–9.
Verdonk K, Saleh L, Lankhorst S, Smilde JEI, van Ingen MM, Garrelds IM, et al. Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression. Hypertension. 2015;65(6):1316–23.
Aggarwal PK, Chandel N, Jain V, Jha V. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. J Hum Hypertens. 2012;26(4):236–41.
Stanhewicz AE, Jandu S, Santhanam L, Alexander LM. Alterations in endothelin type B receptor contribute to microvascular dysfunction in women who have had preeclampsia. Clin Sci (Lond). 2017;131(23):2777–89.
Majali-Martinez A, Velicky P, Pollheimer J, Knöfler M, Yung HW, Burton GJ, et al. Endothelin-1 down-regulates matrix metalloproteinase 14 and 15 expression in human first trimester trophoblasts via endothelin receptor type B. Hum Reprod. 2017;32(1):46–54.
Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med. 2007;28(1):1–22. vii
Safdar Z. Pulmonary hypertension: a woman's disease. Tex Heart Inst J. 2013;40(3):302–3.
Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903.
Kozu K, et al. Sex differences in hemodynamic responses and long-term survival to optimal medical therapy in patients with pulmonary arterial hypertension. Heart Vessel. 2018 (in press).
Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest. 2012;141(1):20–6.
Marra AM, Benjamin N, Eichstaedt C, Salzano A, Arcopinto M, Gargani L, et al. Gender-related differences in pulmonary arterial hypertension targeted drugs administration. Pharmacol Res. 2016;114:103–9.
Mathai SC, Hassoun PM, Puhan MA, Zhou Y, Wise RA. Sex differences in response to tadalafil in pulmonary arterial hypertension. Chest. 2015;147(1):188–97.
Funding
This work was supported by grants from the National Heart Lung and Blood Institute (P01 HL0699499 and P01 HL136267), an American Heart Association Strategically Focused Research Network Grant on Hypertension, and a UAB School of Medicine AMC21 Multi-Investigator Planning Grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Preeclampsia
Rights and permissions
About this article
Cite this article
Gohar, E.Y., Pollock, D.M. Sex-Specific Contributions of Endothelin to Hypertension. Curr Hypertens Rep 20, 58 (2018). https://doi.org/10.1007/s11906-018-0856-0
Published:
DOI: https://doi.org/10.1007/s11906-018-0856-0